{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:01Z","timestamp":1791976501068,"version":"4.4.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      In the last two decades, improvement on asthma treatment has been merely marginal for both adults and children; inhaled corticosteroids (ICS) combined with \u03b2-2-mimetics remain the main therapy [3\n                      <jats:sup>,<\/jats:sup>\n                      4]. \"New\u201d therapies are just variations on ICS or, for children, on various other drugs that were allowed for adult asthma patients (clinicaltrials.gov). Although currently monoclonal antibodies have been intro-duced to the field, there is still a large therapeutic burden, given the mortality rate and widespread prevalence of uncontrolled asthma [2]. A simple and adequate way to reduce distress and costs would have great merit. PDE3 inhibitor enoximone was used earlier in successful treatment of life-threatening bronchial asthma (status asthmaticus) as well as in preoperative settings to prevent patients with severe asthma from suffering major surgery-related exacerbations; also, translational mice models showed the anti-inflammatory effects when PDE3 was targeted. Both outcomes suggested a beneficial effect of enoximone in severe chronic asthma. We hypothesized that enoximone might also be helpful in patients with severe chronic asthma; hence, we treated (and followed) &gt; 70 patients (age 0\u201477, all volunteers) with personalized low doses of enoximone (orally), among them 11 minors, who are described here. Both children and adults reported improvement and\/or alleviation of their asthma symptoms. All patients reported a better quality of life and greater drug compliance. The drug was well tolerated and showed no\/negligible side effects. Notable bonus: asthma-related comorbidities (allergies, eczema, and rhinitis) were reported also to be less severe or even to disappear. The evaluation shows that PDE3 inhibitor enoximone is an adequate alternative for or addition to current asthma therapeutics, as add-on as well as stand-alone, considerably reducing the use of \u03b2-2-mimetics\/ICS, with no or negligible side effects. Additional studies are advisable.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijpam.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T14:02:18Z","timestamp":1613916138000},"page":"147-151","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Oral enoximone allows the reduction and discontinuation of inhaled steroids and beta2 agonists in asthmatic children"],"prefix":"10.4103","volume":"9","author":[{"given":"Jan","family":"Beute","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"KleinJan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-14-20240903","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S2213-2600(19)30197-3","article-title":"Preventing asthma deaths: above all, do no harm","volume":"7","author":"Bush","year":"2019","journal-title":"Lancet Respir Med"},{"key":"R3-14-20240903","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(19)31948-8","article-title":"Budesonide formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRAC-TICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial","volume":"394","author":"Hardy","year":"2019","journal-title":"Lancet"},{"key":"R4-14-20240903","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","article-title":"Controlled trial of budesonide-formoterol as needed for mild asthma","volume":"380","author":"Beasley","year":"2019","journal-title":"N Engl J Med"},{"key":"R5-14-20240903","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/bja\/aes444","article-title":"Inhaled and intravenous therapy in acute severe and life- threatening asthma","volume":"110","author":"Sellers","year":"2013","journal-title":"Br J Anaesth"},{"key":"R7-14-20240903","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/bja\/aeu048","article-title":"Emergency treatment of status asthmaticus with enoximone","volume":"112","author":"Beute","year":"2014","journal-title":"Br J Anaesth"},{"key":"R8-14-20240903","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/2589645801913010012","article-title":"The use of milrinone versus conventional treatment for the management of life-threatening bronchial asthma","volume":"13","author":"Sobhy","year":"2019","journal-title":"Open Anesthesiol J"},{"key":"R9-14-20240903","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00246-016-1433-4","article-title":"Oral enoximone as an alternative to protracted intravenous medication in severe pediatric myocardial failure","volume":"37","author":"Furck","year":"2016","journal-title":"Pediatr Cardiol"},{"key":"R12-14-20240903","first-page":"5057390","article-title":"A loading dose of IV salbutamol in an adolescent with severe acute asthma and cardiac arrest","volume":"2019","author":"Boeschoten","year":"2019","journal-title":"Case Rep Pediatr"},{"key":"R13-14-20240903","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/eurheartj\/ehp338","article-title":"Effects of low- dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the random-ized, double-blind, placebo-controlled, parallel group ESSENTIAL trials","volume":"30","author":"Metra","year":"2009","journal-title":"Eur Heart J"},{"key":"R14-14-20240903","doi-asserted-by":"crossref","first-page":"14771","DOI":"10.1073\/pnas.0506489102","article-title":"A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis","volume":"102","author":"Ding","year":"2005","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"R15-14-20240903","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF00637599","article-title":"The relationship between pharma-cokinetics and pharmacodynamics of enoximone in healthy man","volume":"35","author":"Belz","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-14-20240903","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0385-8146(98)00010-8","article-title":"The effect of selective phosphodiesterase inhibitors on mucociliary activity in the upper and lower airways in vitro","volume":"25","author":"Cervin","year":"1998","journal-title":"Auris Nasus Larynx"},{"key":"R17-14-20240903","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/ATVBAHA.112.300993","article-title":"Prostaglandin D2-DP signaling pro-motes endothelial barrier function via the cAMP\/PKA\/Tiam1\/Rac1 pathway","volume":"33","author":"Kobayashi","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R18-14-20240903","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1124\/jpet.105.083519","article-title":"Dynamic acti-vation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors","volume":"314","author":"Liu","year":"2005","journal-title":"J Pharmacol Exp Therapeut"},{"key":"R19-14-20240903","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1091\/mbc.e09-08-0655","article-title":"Compart-mentalized cyclic adenosine 3\u2019,5\u2019-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains","volume":"21","author":"Penmatsa","year":"2010","journal-title":"Mol Biol Cell"},{"key":"R20-14-20240903","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13223-017-0202-0","article-title":"Asthma pressurised metered dose inhaler performance; propel-lant effect studies in delivery systems","volume":"13","author":"Sellers","year":"2017","journal-title":"Allergy Asthma Clin Immumol"}],"container-title":["International Journal of Pediatrics and Adolescent Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352646721000193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352646721000193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.ijpam.2021.02.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:40:32Z","timestamp":1787845232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.ijpam.2021.02.002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijpam.2021.02.002","relation":{},"ISSN":["2352-6467"],"issn-type":[{"value":"2352-6467","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}